Dynavax Technologies Co. (NASDAQ:DVAX) – Analysts at William Blair dropped their FY2020 EPS estimates for Dynavax Technologies in a research report issued on Tuesday, December 3rd. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings of ($1.10) per share for the year, down from their previous forecast of ($1.09). William Blair currently has a “Buy” rating on the stock. William Blair also issued estimates for Dynavax Technologies’ Q4 2020 earnings at ($0.25) EPS, FY2021 earnings at ($0.68) EPS, FY2022 earnings at ($0.51) EPS and FY2023 earnings at ($0.30) EPS.
Several other research firms have also recently commented on DVAX. Zacks Investment Research upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Wednesday. BidaskClub raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of Dynavax Technologies in a research note on Thursday, November 7th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Dynavax Technologies presently has an average rating of “Buy” and a consensus target price of $12.63.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.10). The firm had revenue of $10.58 million for the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. The firm’s quarterly revenue was up 624.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.65) EPS.
Several hedge funds have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of Dynavax Technologies by 95.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 3,402 shares during the last quarter. Bank of Montreal Can increased its position in shares of Dynavax Technologies by 148.4% in the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 4,445 shares in the last quarter. Wedbush Securities Inc. acquired a new stake in Dynavax Technologies during the 2nd quarter worth $42,000. Ingalls & Snyder LLC acquired a new stake in Dynavax Technologies during the 3rd quarter worth $52,000. Finally, M&T Bank Corp lifted its holdings in Dynavax Technologies by 29.5% during the second quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 3,116 shares in the last quarter. Institutional investors own 82.36% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.
Read More: What is Forex?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.